Two oral ATX inhibitors, GLPG1690 and FTP-180, are currently on trial for idiopathic pulmonary fibrosis [200,201] and ziritaxestat, another orally administered ATX inhibitor, for systemic sclerosis [202]. This evidence concerns the gene ENPP2 and pulmonary fibrosis.